ghk cu and retatrutide + GHK-Cu + Bac Water – Precise Peptides Australia GHK-Cu may Prevent Oxidative Stress

Cardiovascular and Endothelial Benefits GLP-1 RAs have demonstrated robust cardiovascular protection in multiple large-scale trials, including LEADER, REWIND, and SUSTAIN-6, showing reduced rates of major adverse cardiac events independent of weight loss

As a triple incretin receptor agonist, it: Activates GLP-1 receptors , reducing appetite, slowing gastric emptying, and improving insulin secretion Activates GIP receptors , enhancing insulin response and potentially supporting fat metabolism Activates glucagon receptors , increasing energy expenditure and hepatic glucose output Whilst glucagon receptor activation increases hepatic glucose output, the net glycaemic effect of retatrutide is mitigated by the concurrent GLP-1 and GIP activity, resulting in overall improvements in glycaemic control in trial participants

This "weight loss without dieting" mechanism can prompt patients to shift from extreme dieting to balanced nutrition, such as increasing dietary fiber intake and reducing refined carbohydrates, and form a sustainable eating habit

It is reducing the burden enough that patients can continue treatment and capture its long-term benefits without unnecessary suffering along the way